XAIR - Earnings announcements

GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

GARDEN CITY, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it will report financial results for its fiscal fourth quarter and year ended March 31, 2022 on Thursday, June 16, 2022. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. C

LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial launch anticipated in the first half of calendar year 2022 along with European CE Mark Raised $30 million for oncology affiliate Beyond Cancer™, Beyond Air maintained an 80% equity ownership; first in human trial initiation on track for first half of calendar year 2022 Expansion of leadership team with appointment of Dr. Andrew Colin to Chief Medical Officer tasked with leading the strategic efforts for LungFit® PRO and LungFit® GO clinical programs Four abstracts accepted for presentation at leading scientific conferences for ongoing clinical programs in the first half of calendar

GARDEN CITY, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it will report financial results for its third fiscal quarter ended December 31, 2021 on Thursday, February 10, 2022. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.  

U.S. FDA actively reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Remain on track for commercial launch in the fourth quarter of calendar year 2021 Raised $23.9 million to form a new private, independently managed entity, called Beyond Cancer, Ltd, to advance the development of ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors Positive interim results reported from the LungFit® GO Nontuberculous Mycobacteria (NTM) lung infection at-home pilot study (self-administration), with full efficacy and safety data expected in CY2022 Conference call scheduled for today, November 11th, at 4:30

$23.9 million committed in concurrent equity private placement to form Beyond Cancer that will leverage Beyond Air's nitric oxide (NO) expertise and take over development of current solid tumor pipeline Beyond Cancer is led by Selena Chaisson, M.D., as Chief Executive Officer, as well as a seasoned leadership team with experience in emerging healthcare companies and clinical oncology Ultra-high concentration NO (UNO) has shown anticancer properties in preclinical trials by eliciting an immune response which confers immunity to the host Transaction enables Beyond Air to focus on its core business of advancing LungFit® for respiratory diseases, and Beyond Cancer to accelerate development o

GARDEN CITY, N.Y., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its second fiscal quarter ended September 30, 2021 on Thursday, November 11, 2021. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. Conference Call & WebcastThursday, November 11th @ 4:30 PM ETDomes

U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of calendar year 2021 Anticipate reporting interim results from the LungFit® GO Nontuberculous Mycobacteria (NTM) lung infection at-home pilot study (self-administration) in Fall 2021 Positive data presented at American Thoracic Society in May 2021 from acute viral pneumonia (including COVID-19) study using LungFit® PRO at 150 ppm NO Solid tumor program expected to receive regulatory clearance to initiate first in human studies by the end of calendar year 2021 Conference call scheduled for today, Augu

GARDEN CITY, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its first fiscal quarter ended June 30, 2021 on Tuesday, August 10, 2021. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day. Conference Call & WebcastTuesday, August 10th @ 4:30 PM ETDomestic:  877-

Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial launch in the fourth quarter of calendar year 2021 Expanded the commercial and business development teams by appointing executives with extensive nitric oxide (NO) experience Presented positive data for 150 – 160 ppm NO from LungFit® PRO programs in hospitalized patients (adults and infants) with viral lung infections at CHEST 2020 and at ATS 2021 Received grant from the Cystic Fibrosis Foundation (CFF) for ongoing nontuberculous mycobacteria (NTM) at-home pilot study delivering up to 250 pp

U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization Interim results from the acute viral pneumonia (including SARS-CoV-2) pilot study using 150 ppm nitric oxide (NO) with LungFitTM PRO expected in Spring 2021 Interim results expected mid-calendar year 2021 for Nontuberculous Mycobacteria (NTM) lung infection at-home pilot study where NO is self-administered at concentrations up to 250 ppm nitric oxide with LungFitTM GO Conference call scheduled for today, February 9th, at 4:30 p.m. ET GARDEN CITY, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDA